FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1532912772> ?p ?o ?g. }

• W1532912772 abstract "Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy. To reduce these effects, the World Health Organization recommends that pregnant women living in malaria endemic areas sleep under insecticide-treated bednets, are treated for malaria illness and anaemia, and receive chemoprevention with an effective antimalarial drug during the second and third trimesters.To assess the effects of malaria chemoprevention given to pregnant women living in malaria endemic areas on substantive maternal and infant health outcomes. We also summarised the effects of intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) alone, and preventive regimens for Plasmodium vivax.We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and reference lists up to 1 June 2014.Randomized controlled trials (RCTs) and quasi-RCTs of any antimalarial drug regimen for preventing malaria in pregnant women living in malaria-endemic areas compared to placebo or no intervention. In the mother, we sought outcomes that included mortality, severe anaemia, and severe malaria; anaemia, haemoglobin values, and malaria episodes; indicators of malaria infection, and adverse events. In the baby, we sought foetal loss, perinatal, neonatal and infant mortality; preterm birth and birthweight measures; and indicators of malaria infection. We included regimens that were known to be effective against the malaria parasite at the time but may no longer be used because of parasite drug resistance.Two review authors applied inclusion criteria, assessed risk of bias and extracted data. Dichotomous outcomes were compared using risk ratios (RR), and continuous outcomes using mean differences (MD); both are presented with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach.Seventeen trials enrolling 14,481 pregnant women met our inclusion criteria. These trials were conducted between 1957 and 2008, in Nigeria (three trials), The Gambia (three trials), Kenya (three trials), Mozambique (two trials), Uganda (two trials), Cameroon (one trial), Burkina Faso (one trial), and Thailand (two trials). Six different antimalarials were evaluated against placebo or no intervention; chloroquine (given weekly), pyrimethamine (weekly or monthly), proguanil (daily), pyrimethamine-dapsone (weekly or fortnightly), and mefloquine (weekly), or intermittent preventive therapy with SP (given twice, three times or monthly). Trials recruited women in their first or second pregnancy (eight trials); only multigravid women (one trial); or all women (eight trials). Only six trials had adequate allocation concealment.For women in their first or second pregnancy, malaria chemoprevention reduces the risk of moderate to severe anaemia by around 40% (RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants, high quality evidence), and the risk of any anaemia by around 17% (RR 0.83, 95% CI 0.74 to 0.93; five trials,, 3662 participants, high quality evidence). Malaria chemoprevention reduces the risk of antenatal parasitaemia by around 61% (RR 0.39, 95% CI 0.26 to 0.58; seven trials, 3663 participants, high quality evidence), and two trials reported a reduction in febrile illness (low quality evidence). There were only 16 maternal deaths and these trials were underpowered to detect an effect on maternal mortality (very low quality evidence).For infants of women in their first and second pregnancies, malaria chemoprevention probably increases mean birthweight by around 93 g (MD 92.72 g, 95% CI 62.05 to 123.39; nine trials, 3936 participants, moderate quality evidence), reduces low birthweight by around 27% (RR 0.73, 95% CI 0.61 to 0.87; eight trials, 3619 participants, moderate quality evidence), and reduces placental parasitaemia by around 46% (RR 0.54, 95% CI 0.43 to 0.69; seven trials, 2830 participants, high quality evidence). Fewer trials evaluated spontaneous abortions, still births, perinatal deaths, or neonatal deaths, and these analyses were underpowered to detect clinically important differences.In multigravid women, chemoprevention has similar effects on antenatal parasitaemia (RR 0.38, 95% CI 0.28 to 0.50; three trials, 977 participants, high quality evidence)but there are too few trials to evaluate effects on other outcomes.In trials giving chemoprevention to all pregnant women irrespective of parity, the average effects of chemoprevention measured in all women indicated it may prevent severe anaemia (defined by authors, but at least < 8 g/L: RR 0.19, 95% CI 0.05 to 0.75; two trials, 1327 participants, low quality evidence), but consistent benefits have not been shown for other outcomes.In an analysis confined only to intermittent preventive therapy with SP, the estimates of effect and the quality of the evidence were similar.A summary of a single trial in Thailand of prophylaxis against P. vivax showed chloroquine prevented vivax infection (RR 0.01, 95% CI 0.00 to 0.20; one trial, 942 participants).Routine chemoprevention to prevent malaria and its consequences has been extensively tested in RCTs, with clinically important benefits on anaemia and parasitaemia in the mother, and on birthweight in infants." @default.
• W1532912772 created "2016-06-24" @default.
• W1532912772 creator A5007223498 @default.
• W1532912772 creator A5014755048 @default.
• W1532912772 creator A5022466290 @default.
• W1532912772 creator A5024749902 @default.
• W1532912772 creator A5044576485 @default.
• W1532912772 date "2014-10-10" @default.
• W1532912772 modified "2023-10-02" @default.
• W1532912772 title "Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment" @default.
• W1532912772 cites W132337903 @default.
• W1532912772 cites W1492141128 @default.
• W1532912772 cites W1548636822 @default.
• W1532912772 cites W1552589842 @default.
• W1532912772 cites W1670221772 @default.
• W1532912772 cites W1760515944 @default.
• W1532912772 cites W1785427672 @default.
• W1532912772 cites W1820074434 @default.
• W1532912772 cites W1826591510 @default.
• W1532912772 cites W1829384068 @default.
• W1532912772 cites W1829969880 @default.
• W1532912772 cites W1842023087 @default.
• W1532912772 cites W1860293246 @default.
• W1532912772 cites W1868725605 @default.
• W1532912772 cites W1879866405 @default.
• W1532912772 cites W1963973299 @default.
• W1532912772 cites W1966870089 @default.
• W1532912772 cites W1967245909 @default.
• W1532912772 cites W1968686750 @default.
• W1532912772 cites W1969763842 @default.
• W1532912772 cites W1975654238 @default.
• W1532912772 cites W1991775785 @default.
• W1532912772 cites W1999132849 @default.
• W1532912772 cites W2001075485 @default.
• W1532912772 cites W2006928697 @default.
• W1532912772 cites W2012988572 @default.
• W1532912772 cites W2014751678 @default.
• W1532912772 cites W2023607994 @default.
• W1532912772 cites W2033831018 @default.
• W1532912772 cites W2036438666 @default.
• W1532912772 cites W2041022679 @default.
• W1532912772 cites W2049453239 @default.
• W1532912772 cites W2052594377 @default.
• W1532912772 cites W2054150443 @default.
• W1532912772 cites W2055472319 @default.
• W1532912772 cites W2065168272 @default.
• W1532912772 cites W2066452525 @default.
• W1532912772 cites W2067593593 @default.
• W1532912772 cites W2084206772 @default.
• W1532912772 cites W2091979677 @default.
• W1532912772 cites W2102280420 @default.
• W1532912772 cites W2103369466 @default.
• W1532912772 cites W2103871138 @default.
• W1532912772 cites W2106773795 @default.
• W1532912772 cites W2108741937 @default.
• W1532912772 cites W2109179635 @default.
• W1532912772 cites W2111580380 @default.
• W1532912772 cites W2117002844 @default.
• W1532912772 cites W2122472628 @default.
• W1532912772 cites W2124783234 @default.
• W1532912772 cites W2129733872 @default.
• W1532912772 cites W2138981018 @default.
• W1532912772 cites W2141790247 @default.
• W1532912772 cites W2142389365 @default.
• W1532912772 cites W2143784127 @default.
• W1532912772 cites W2147144239 @default.
• W1532912772 cites W2149746703 @default.
• W1532912772 cites W2150567785 @default.
• W1532912772 cites W2152091160 @default.
• W1532912772 cites W2152609980 @default.
• W1532912772 cites W2153401529 @default.
• W1532912772 cites W2153428862 @default.
• W1532912772 cites W2157428891 @default.
• W1532912772 cites W2163171935 @default.
• W1532912772 cites W2166068761 @default.
• W1532912772 cites W2166773458 @default.
• W1532912772 cites W2168448634 @default.
• W1532912772 cites W2229047353 @default.
• W1532912772 cites W2255581309 @default.
• W1532912772 cites W2285608358 @default.
• W1532912772 cites W2295102945 @default.
• W1532912772 cites W2296341665 @default.
• W1532912772 cites W2310319955 @default.
• W1532912772 cites W2795602188 @default.
• W1532912772 cites W4232323670 @default.
• W1532912772 doi "https://doi.org/10.1002/14651858.cd000169.pub3" @default.
• W1532912772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4498495" @default.
• W1532912772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25300703" @default.
• W1532912772 hasPublicationYear "2014" @default.
• W1532912772 type Work @default.
• W1532912772 sameAs 1532912772 @default.
• W1532912772 citedByCount "66" @default.
• W1532912772 countsByYear W15329127722015 @default.
• W1532912772 countsByYear W15329127722016 @default.
• W1532912772 countsByYear W15329127722017 @default.
• W1532912772 countsByYear W15329127722018 @default.
• W1532912772 countsByYear W15329127722019 @default.
• W1532912772 countsByYear W15329127722020 @default.
• W1532912772 countsByYear W15329127722021 @default.
• W1532912772 countsByYear W15329127722022 @default.

• next